-24-year annual sales also increased by 3 times compared to 23-year
-Expanding cooperation with pharmaceutical companies… Operating a total of 5 disease drug cost support programs by the second half of the year
Rarenote, a platform dedicated to rare disease and cancer patients, announced on the 30th that it has exceeded its 2024 annual sales with just the first half of 2025 performance. Its 2024 annual sales also increased 3.3 times compared to the previous year, proving the platform's growth potential and market demand.
RareNote is a service developed by digital healthcare company Humanscape to solve the information asymmetry problem experienced by patients with rare diseases and cancer. In cooperation with pharmaceutical companies, it operates a drug cost support program to reduce the financial burden on patients for expensive drug treatment.
This program is a method in which pharmaceutical companies reimburse a portion of the treatment costs paid by patients. Previously, most of the application, review, and result notification were done manually. Rarenote digitized the entire process, greatly improving the work efficiency of pharmaceutical companies as well as the accessibility and convenience of information for patients.
In just six months since launching the service, it has provided substantial treatment cost support benefits to approximately 100 patients, and is currently collaborating with a number of pharmaceutical companies, including AstraZeneca and BeiGene Korea.
By the second half of this year, we plan to operate programs for a total of five diseases and execute a patient support fund of approximately 2.5 billion won. Rarenote expects to continue to grow with the digital-based drug cost support program as its core service.
“Rarenote is a platform with data-based accessibility and operational efficiency that provides real help to patients while establishing itself as a trustworthy partner to pharmaceutical companies,” said Jang Min-hu, CEO of Humanscape. “We will continue to provide value to more patients and partners through sustainable business growth.”
You must be logged in to post a comment.